Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
← catalyst calendarNCT05329649 · readout in 291 d
Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →. With CRISPR Therapeutics.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
13actual
Sites
7
Countries
Germany, Italy, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-02 | actual | When the study began enrolling |
| Primary completion | 2027-06-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-06 | estimated | The whole study's end, after follow-up |
| First posted | 2022-04-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Sickle Cell Disease
- Hydroxyurea Failure
- Hydroxyurea Intolerance
- Hemoglobinopathies
- Hematological Diseases
Intervention
- Biological: CTX001 — also filed as Exagamglogene autotemcel, Exa-cel
Primary outcome
what the primary-completion date above is the date OFProportion of Participants who do not Have any Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months (VF12)
measured Up to 24 Months After CTX001 Infusion
Publications
- PMID 42274009 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed